Asthma Pipeline, Market Trends, and Drug Development Analysis: 25+ Emerging Therapies and Key Companies Transforming the Future of Asthma Treatment Market | DelveInsight

DelveInsight's Asthma Pipeline Insight 2026 report provides comprehensive global coverage of marketed and pipeline asthma therapies across various stages of clinical development. The report delivers valuable insights into the evolving asthma treatment landscape, emerging asthma drugs, competitive dynamics, market trends, treatment innovations, and future opportunities shaping the asthma drug market and respiratory disease industry.

Key Takeaways from the Asthma Pipeline and Treatment Landscape Report
• DelveInsight's asthma pipeline analysis highlights a dynamic development landscape with more than 25 active therapies being evaluated across multiple stages of clinical development.
• Leading asthma companies including Areteia Therapeutics, Amgen, Jasper Therapeutics, Haisco Pharmaceutical Group, Kinaset Therapeutics, Uniquity Bio, ImmuPharma, and others are actively advancing innovative asthma treatment candidates.
• Promising asthma pipeline therapies include Dexpramipexole, Rocatinlimab, HSK31858, Briquilimab, IBI3002, Solriktug, Forigerimod, and others.
• Increasing research investments, novel biologic therapies, and precision medicine approaches are driving significant growth in the asthma therapeutics market and reshaping future treatment paradigms.
• Rising disease prevalence and expanding clinical research activities continue to create substantial opportunities across the global asthma drug market and respiratory therapeutics industry.

Request a sample and explore the latest advancements in asthma treatment, asthma market trends, and emerging asthma drugs. https://www.delveinsight.com/sample-request/asthma-pipelineinsight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr

What is Asthma?
Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways, leading to breathing difficulties and recurrent respiratory symptoms. The condition affects millions of individuals worldwide and remains a significant healthcare burden.
Asthma symptoms commonly include shortness of breath, wheezing, coughing, chest tightness, and respiratory discomfort. During asthma attacks, airway inflammation, bronchospasm, and excessive mucus production contribute to airflow obstruction.
According to DelveInsight's assessment, asthma affects more than 25 million people in the United States, including over 5 million children, highlighting the substantial patient population driving demand across the asthma treatment market.
The growing prevalence of asthma, coupled with increasing awareness and advancements in diagnostic technologies, continues to influence asthma market size, treatment adoption, and industry growth worldwide.

Emerging Asthma Drug Profiles

Dexpramipexole: Areteia Therapeutics
Dexpramipexole is a first-in-class oral eosinophil maturation inhibitor being developed by Areteia Therapeutics for eosinophilic asthma. The therapy works by inhibiting the maturation and release of eosinophils from the bone marrow, thereby reducing peripheral blood eosinophil levels associated with airway inflammation. Currently, Dexpramipexole is being evaluated in Phase III clinical development for asthma treatment.
In clinical studies, Dexpramipexole demonstrated significant reductions in eosinophil counts and exhibited a favorable safety profile, supporting its potential as a novel treatment option within the asthma drug market.

Briquilimab: Jasper Therapeutics, Inc.
Briquilimab is an investigational monoclonal antibody targeting the proto-oncogene protein c-Kit pathway. The therapy is being evaluated as a subcutaneous treatment for asthma and is currently in Phase I clinical development. The candidate represents an innovative approach aimed at addressing underlying inflammatory mechanisms associated with asthma progression.

Learn more about the novel and emerging asthma pipeline therapies and future treatment innovations shaping the asthma treatment market. https://www.delveinsight.com/sample-request/asthma-pipelineinsight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr

Recent Developments in the Asthma Clinical Trial and Drug Market Landscape
• In February 2025, Enveda announced the evaluation of its lead asset, ENV-294, in asthma, expanding its development strategy into respiratory inflammatory diseases and strengthening the asthma pipeline landscape.
• In December 2024, Jasper Therapeutics announced dosing of the first patient in the Phase Ib/IIa ETESIAN study evaluating Briquilimab in allergic asthma, marking an important milestone in the company's asthma development program.
• In March 2024, Upstream Bio initiated patient dosing in the Phase II VALIANT clinical trial evaluating Verekitug (UPB-101) in severe asthma, highlighting continued innovation within the asthma treatment industry.
• In February 2024, Areteia Therapeutics secured an additional USD 75 million in Series A financing to support expansion of its Phase III Dexpramipexole development program for eosinophilic asthma, bringing total Series A funding to USD 425 million.
• In February 2023, Dexpramipexole received an Innovation Passport designation from the UK's MHRA for eosinophilic asthma, supporting accelerated development efforts.

Scope of the Asthma Pipeline Report
Coverage: Global
Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy
Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III
Therapeutic Assessment by Route of Administration: Oral, Subcutaneous, Inhalation, Intravenous
Therapeutic Assessment by Molecule Type: Small Molecules, Monoclonal Antibodies, Bispecific Antibodies, Immunomodulators, and Others
Key Asthma Companies: Areteia Therapeutics, Amgen, Jasper Therapeutics, Haisco Pharmaceutical Group, Kinaset Therapeutics, Uniquity Bio, ImmuPharma, and others.
Key Asthma Pipeline Therapies: Dexpramipexole, Rocatinlimab, HSK31858, Briquilimab, IBI3002, Solriktug, Forigerimod, and others.

The report provides actionable intelligence regarding asthma market size, treatment trends, drug development strategies, competitive landscape analysis, industry opportunities, and future commercial potential.

Dive deep into rich insights for new asthma drugs, clinical trial developments, asthma market size, market share, competitive landscape, and future forecasts. https://www.delveinsight.com/sample-request/asthma-pipelineinsight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr

Table of Contents
• Asthma Pipeline Report Introduction
• Asthma Pipeline Executive Summary
• Asthma Disease Overview
• Asthma Epidemiology and Treatment Landscape
• Asthma Pipeline Therapeutics
• Comparative Pipeline Analysis
• Late-Stage Products (Phase III)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I)
• Preclinical and Discovery-Stage Products
• Therapeutic Assessment
• Route of Administration Analysis
• Molecule Type Analysis
• Product Type Analysis
• Collaborations and Licensing Assessment
• Asthma Market Drivers and Barriers
• Unmet Needs Assessment
• Future Market Outlook
• Analyst Views
• Appendix

For further information on the asthma pipeline therapeutics, emerging treatment landscape, and competitive intelligence, reach out to DelveInsight today. https://www.delveinsight.com/sample-request/asthma-pipelineinsight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.